MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc DIO Ratio 2011-2026 | PRGO
Annual DIO Ratio Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 148 | 143 | 141 | 132 | 149 | 153 | 115 | 110 | 99.3 | 89.9 | 106 | 88.3 | 114 | 96.2 | 102 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 153 | 88.3 | 119 |
Quarterly DIO Ratio Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 167 | 156 | 157 | - | 150 | 152 | 142 | - | 148 | 140 | 139 | - | 134 | 128 | 126 | - | 143 | 163 | 156 | - | 153 | 161 | 134 | - | 113 | 123 | 116 | - | 113 | 112 | 106 | - | 100 | 100 | 100 | - | 93.3 | 91.4 | 94.9 | - | 111 | 101 | 88.3 | 86.1 | 93.2 | 44.6 | 98.5 | 104 | 111 | 51.9 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 167 | 44.6 | 120 |
DIO Ratio of other stocks in the Drug manufacturers industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
133 | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
58.7 | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
459 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
82.7 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
48.9 | - | 0.86 % | $ 117 M | USA |
 |
Canopy Growth Corporation
CGC
|
167 | $ 0.95 | -2.04 % | $ 102 M |  Canada |
 |
Aurora Cannabis
ACB
|
1.35 K | $ 3.29 | -0.61 % | $ 86.3 M | Canada |
 |
China Pharma Holdings
CPHI
|
168 | $ 0.63 | - | $ 11 M |  China |
 |
Catalent
CTLT
|
71.9 | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
158 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
366 | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
221 | $ 2.51 | -0.31 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
460 | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
176 | $ 7.96 | -1.12 % | $ 408 M | USA |
 |
Endo International plc
ENDP
|
100 | - | - | $ 28.9 M |  Irlanda |
 |
Pacira BioSciences
PCRX
|
246 | $ 22.63 | -0.09 % | $ 1.05 B | USA |
 |
Evoke Pharma
EVOK
|
995 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
703 | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
239 | $ 3.15 | 3.28 % | $ 44.3 M | USA |
 |
Rockwell Medical
RMTI
|
28.5 | $ 1.05 | 2.45 % | $ 24.5 M | USA |
 |
Bausch Health Companies
BHC
|
172 | $ 4.98 | -2.35 % | $ 1.82 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
117 | $ 2.39 | -6.13 % | $ 2.97 M | USA |
 |
Harrow Health
HROW
|
65.1 | $ 35.27 | 3.74 % | $ 1.3 B | USA |
 |
OptiNose
OPTN
|
370 | - | - | $ 1.08 B | USA |
 |
Tilray
TLRY
|
170 | $ 6.43 | -0.31 % | $ 3.97 B | Canada |
 |
Evolus
EOLS
|
71.3 | $ 4.61 | -1.6 % | $ 297 M | USA |
 |
Veru
VERU
|
179 | $ 2.3 | - | $ 310 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
149 | - | -39.89 % | $ 27.7 M | USA |
 |
Viatris
VTRS
|
140 | $ 13.43 | 1.02 % | $ 16.1 B | USA |
 |
OrganiGram Holdings
OGI
|
2.83 K | $ 1.36 | - | $ 402 M | Canada |
 |
PetIQ
PETQ
|
64.9 | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
97.2 | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
30.1 | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
59.7 | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
204 | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
127 | - | 1.15 % | $ 7.11 M | USA |
 |
TherapeuticsMD
TXMD
|
1.04 K | $ 2.35 | 1.73 % | $ 24.5 M | USA |
 |
cbdMD
YCBD
|
165 | $ 0.78 | 2.25 % | $ 3.36 M | USA |
 |
Organogenesis Holdings
ORGO
|
85.9 | $ 2.42 | -2.23 % | $ 319 M | USA |
 |
Assertio Holdings
ASRT
|
322 | $ 15.21 | 8.64 % | $ 97.4 M | USA |
 |
Recro Pharma
REPH
|
49.1 | - | -4.76 % | $ 65.3 M | USA |